HomeCompareAMGN vs RSG

AMGN vs RSG: Dividend Comparison 2026

AMGN yields 2.74% · RSG yields 1.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AMGN wins by $119.4K in total portfolio value
10 years
AMGN
AMGN
● Live price
2.74%
Share price
$351.98
Annual div
$9.66
5Y div CAGR
48.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$161.7K
Annual income
$68,348.66
Full AMGN calculator →
RSG
RSG
● Live price
1.09%
Share price
$220.35
Annual div
$2.41
5Y div CAGR
44.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$42.2K
Annual income
$7,673.62
Full RSG calculator →

Portfolio growth — AMGN vs RSG

📍 AMGN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMGNRSG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMGN + RSG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMGN pays
RSG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMGN
Annual income on $10K today (after 15% tax)
$233.28/yr
After 10yr DRIP, annual income (after tax)
$58,096.36/yr
RSG
Annual income on $10K today (after 15% tax)
$92.97/yr
After 10yr DRIP, annual income (after tax)
$6,522.58/yr
At 15% tax rate, AMGN beats the other by $51,573.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMGN + RSG for your $10,000?

AMGN: 50%RSG: 50%
100% RSG50/50100% AMGN
Portfolio after 10yr
$101.9K
Annual income
$38,011.14/yr
Blended yield
37.29%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on RSG right now

AMGN
Analyst Ratings
22
Buy
13
Hold
3
Sell
Consensus: Buy
Price Target
$347.73
-1.2% upside vs current
Range: $185.00 — $432.00
Altman Z
2.3
Piotroski
8/9
RSG
Analyst Ratings
20
Buy
15
Hold
Consensus: Buy
Price Target
$239.82
+8.8% upside vs current
Range: $220.00 — $255.00
Altman Z
3.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMGN buys
10
RSG buys
6
PoliticianChamberTickerTypeAmountDate
David Taylor🏢 House$AMGN▼ Sell$1,001 - $15,0002026-02-26
David Taylor🏢 House$AMGN▼ Sell$1,001 - $15,0002026-01-29
David Taylor🏢 House$AMGN▲ Buy$1,001 - $15,0002026-01-16
Julie Johnson🏢 House$RSG▼ Sell$1,001 - $15,0002025-12-18
David Taylor🏢 House$AMGN▼ Sell$1,001 - $15,0002025-12-03
David Taylor🏢 House$AMGN▼ Sell$1,001 - $15,0002025-12-03
Julie Johnson🏢 House$RSG▼ Sell$1,001 - $15,0002025-11-13
Marjorie Taylor Greene🏢 House$AMGN▲ Buy$1,001 - $15,0002025-10-24
Lisa McClain🏢 House$AMGN▼ Sell$1,001 - $15,0002025-09-25
Marjorie Taylor Greene🏢 House$AMGN▲ Buy$1,001 - $15,0002025-09-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMGNRSG
Forward yield2.74%1.09%
Annual dividend / share$9.66$2.41
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR48.6%44.6%
Portfolio after 10y$161.7K$42.2K
Annual income after 10y$68,348.66$7,673.62
Total dividends collected$131.4K$20.0K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyBuy
Analyst price target$347.73$239.82

Year-by-year: AMGN vs RSG ($10,000, DRIP)

YearAMGN PortfolioAMGN Income/yrRSG PortfolioRSG Income/yrGap
1← crossover$11,108$407.83$10,858$158.15+$250.00AMGN
2$12,515$629.13$11,850$232.07+$665.00AMGN
3$14,375$984.38$13,022$342.27+$1.4KAMGN
4$16,951$1,570.32$14,442$508.28+$2.5KAMGN
5$20,710$2,571.73$16,215$761.79+$4.5KAMGN
6$26,523$4,363.44$18,506$1,155.85+$8.0KAMGN
7$36,140$7,760.85$21,584$1,782.71+$14.6KAMGN
8$53,357$14,686.42$25,904$2,809.88+$27.5KAMGN
9$87,204$30,112.48$32,275$4,557.44+$54.9KAMGN
10$161,657$68,348.66$42,208$7,673.62+$119.4KAMGN

AMGN vs RSG: Complete Analysis 2026

AMGNHealthcare

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Full AMGN Calculator →

RSGStock

Republic Services, Inc., together with its subsidiaries, offers environmental services in the United States. The company offers collection and processing of recyclable materials, collection, transfer and disposal of non-hazardous solid waste, and other environmental solutions. Its collection services include curbside collection of material for transport to transfer stations, landfills, or recycling processing centers; supply of recycling and waste containers; and renting of compactors. In addition, the company engages in the processing and sale of old corrugated containers, old newsprint, aluminum, glass, and other materials; and provision of landfill and transfer services. Further, it offers disposal of non-hazardous solid and liquid material and in-plant services, such as transportation and logistics. It serves small-container, large-container, and residential customers. As of December 31, 2021, the company operated through 356 collection operations, 239 transfer stations, 198 active landfills, 71 recycling processing centers, 6 saltwater disposal wells, and 7 deep injection wells, as well as 3 treatment, recovery, and disposal facilities in 41 states. It also operated 77 landfill gas-to-energy and renewable energy projects and had 124 closed landfills. The company was incorporated in 1996 and is based in Phoenix, Arizona.

Full RSG Calculator →
📬

Get this AMGN vs RSG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMGN vs SCHDAMGN vs JEPIAMGN vs OAMGN vs KOAMGN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.